Salvage treatment for PCNSL
| Treatment, Ref. . | Study . | No. . | Median age, y . | Prior RT, % . | CR + PR, % . | PFS . | OS . | 1-y OS, % . | Grade 3-4 neutropenia, % . | Grade 3-4 thrombocytopenia, % . | Other toxicities, % . |
|---|---|---|---|---|---|---|---|---|---|---|---|
| VP16 + Ifosfamide + Ara-C97 | R | 16 | 54 | 100 | 37 + 0 | 4.5 | 6.0 | 41 | 69 | 50 | 37 |
| i. a. Carboplatin ± VP16 ± CTX ± RT98 | R | 37 | 57 | 24 | 24 + 11 | 3.0 | 6.8 | 25 | 22 | 19 | > 30 |
| Methotrexate85 | R | 22 | 58 | 14 | 73 + 19 | 26 | 26 | 70 | 5 | 5 | 36 |
| Temozolomide + rituximab99 | R | 15 | 69 | 13 | 40 + 13 | 2.2 | 10.5 | 58 | 7 | 27 | 7 |
| Topotecan45 | P | 27 | 51 | 52 | 19 + 14 | 2.0 | 8.4 | 39 | 26 | 15 | 11 |
| Temozolomide42 | P | 36 | 60 | 86 | 25 + 6 | 2.8 | 4.0 | 31 | 6 | 3 | 3 |
| Rituximab46 | P | 9 | NR | 9 | 11 + 22 | 3.7 | NR | NR | 0 | 0 | 44* |
| Radiotherapy68 | R | 27 | 67 | — | 37 + 37 | 9.7 | 10.9 | 49 | NR | NR | 15† |
| Radiotherapy100 | R | 20 | NR | — | 60 + NR | NR | 19.0 | NR | NR | NR | 58† |
| Treatment, Ref. . | Study . | No. . | Median age, y . | Prior RT, % . | CR + PR, % . | PFS . | OS . | 1-y OS, % . | Grade 3-4 neutropenia, % . | Grade 3-4 thrombocytopenia, % . | Other toxicities, % . |
|---|---|---|---|---|---|---|---|---|---|---|---|
| VP16 + Ifosfamide + Ara-C97 | R | 16 | 54 | 100 | 37 + 0 | 4.5 | 6.0 | 41 | 69 | 50 | 37 |
| i. a. Carboplatin ± VP16 ± CTX ± RT98 | R | 37 | 57 | 24 | 24 + 11 | 3.0 | 6.8 | 25 | 22 | 19 | > 30 |
| Methotrexate85 | R | 22 | 58 | 14 | 73 + 19 | 26 | 26 | 70 | 5 | 5 | 36 |
| Temozolomide + rituximab99 | R | 15 | 69 | 13 | 40 + 13 | 2.2 | 10.5 | 58 | 7 | 27 | 7 |
| Topotecan45 | P | 27 | 51 | 52 | 19 + 14 | 2.0 | 8.4 | 39 | 26 | 15 | 11 |
| Temozolomide42 | P | 36 | 60 | 86 | 25 + 6 | 2.8 | 4.0 | 31 | 6 | 3 | 3 |
| Rituximab46 | P | 9 | NR | 9 | 11 + 22 | 3.7 | NR | NR | 0 | 0 | 44* |
| Radiotherapy68 | R | 27 | 67 | — | 37 + 37 | 9.7 | 10.9 | 49 | NR | NR | 15† |
| Radiotherapy100 | R | 20 | NR | — | 60 + NR | NR | 19.0 | NR | NR | NR | 58† |
Studies focused on HDC/ASCT are reported in Table 2.
P indicates prospective; R, retrospective; RT, radiotherapy; PCNSL, primary CNS lymphoma; CR, complete response; PR, partial response; PFS, median progression-free survival; OS, median overall survival; i.a., intra-arterial; VP16, etoposide; ara-C, high-dose cytarabine; —, not applicable; NR, not reported; and CTX, cyclophosphamide.
Allergic reaction, fatigue, anxiety, and pain.
Neurotoxicity.